Paclitaxel for Injection (Albumin-Bound) from Sino Biopharmaceutical Ltd - breast cancer therapy with nab-paclitaxel in China

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-23, 03:10. Details in the imprint.

Paclitaxel for Injection (Albumin-Bound) from Sino Biopharmaceutical Ltd sits in a clear glass vial, the powder clinging to the glass like fine chalk before reconstitution on the ward. For oncologist Dr. Li Wei, this nab-paclitaxel option feels like one more practical tool when first-line breast cancer regimens start to narrow.

What this nab-paclitaxel does

Paclitaxel for Injection (Albumin-Bound) is Sino Biopharm's branded version of nab-paclitaxel, an albumin-bound formulation of paclitaxel used for metastatic breast cancer and other solid tumors in China. It uses human serum albumin nanoparticles instead of the older Cremophor EL solvent system, which can reduce solvent-related hypersensitivity reactions and simplify premedication protocols.

The drug follows the reference model of Abraxane, combining paclitaxel with albumin to improve delivery to tumors via receptor-mediated transport. Sino Biopharm, through its subsidiary Beijing Tide, has positioned the product in oncology portfolios where taxanes remain a backbone of systemic therapy alongside platinum agents and targeted drugs.

Indications and dosing in practice

Regulatory documents show Paclitaxel for Injection (Albumin-Bound) indicated for metastatic breast cancer patients who have failed first-line therapies, as well as for certain non-small cell lung cancer and pancreatic cancer settings, mirroring international nab-paclitaxel use. In Chinese clinical practice, oncologists typically administer 260 mg/m² every three weeks or 100–125 mg/m² on weekly schedules, depending on tumor type and tolerance.

For nurses on the day ward, the tactile routine is familiar: the lyophilized cake is reconstituted with normal saline, gently swirled until the suspension turns uniformly milky, then hung as a short infusion without the need for Cremophor-driven premedication. That shorter chair time is something Dr. Li quietly welcomes on busy clinic days.

Safety profile and monitoring

Like other taxanes, nab-paclitaxel carries predictable toxicities: neutropenia, peripheral neuropathy, fatigue and alopecia remain the main trade-offs for tumor control. Albumin-bound formulations avoid castor oil solvents but do not remove the need for close blood count monitoring and dose adjustments in frail patients.

Sino Biopharm's labeling highlights peripheral nerve toxicity as a key adverse event, with recommendations to reduce or hold treatment when grade 3 neuropathy appears. For patients, that translates to tingling fingers, difficulty buttoning shirts and sometimes a forced pause in therapy that can feel longer than the calendar suggests.

Where it fits in Sino Biopharm's lineup

Oncology is a core pillar for Sino Biopharm, spanning small molecules, monoclonal antibodies and cytotoxics such as this albumin-bound paclitaxel. Management under chairman Tse Ping has repeatedly emphasized cancer and hepatitis as strategic focus areas, using in-licensing and co-development to fill portfolio gaps.

Paclitaxel for Injection (Albumin-Bound) slots alongside other cancer drugs like pemetrexed and targeted therapies, helping the company compete with multinational brands while offering locally manufactured options for Chinese hospitals. Pricing tends to track national reimbursement negotiations, which shape margins but also drive volume once drugs secure inclusion on the reimbursement list.

Market access and reimbursement in China

Public procurement systems and the national reimbursement drug list are decisive for how widely nab-paclitaxel formulations are used in China. When a cytotoxic like albumin-bound paclitaxel enters centralized procurement, hospitals see lower unit prices but often higher patient access because out-of-pocket burdens fall.

For families arriving at tertiary centers in Beijing or Nanjing, the key question is rarely the formulation science. It is whether Paclitaxel for Injection (Albumin-Bound) sits on the reimbursement list that their provincial fund will honor, and how many cycles their household budget can stretch to match.

Clinical competition and future outlook

Clinically, Sino Biopharm's nab-paclitaxel competes against generic paclitaxel, docetaxel and imported or domestic versions of albumin-bound paclitaxel from rivals. As newer targeted agents and immunotherapies expand into breast and lung cancer lines, classical taxanes may shift gradually toward combination backbones rather than monotherapy centers.

Yet as Dr. Li notes between patient consultations, having a reliable albumin-bound paclitaxel matters when immune checkpoint inhibitors are contraindicated or inaccessible. In those cases, the old taxane logic still holds: dose intensity, careful timing and a regimen patients can physically tolerate over months, not just cycles.

Company context and stock angle

Paclitaxel for Injection (Albumin-Bound) underscores Sino Biopharm's strategy of maintaining a broad oncology portfolio that balances innovative biologics with established chemotherapies. On the Hong Kong Stock Exchange, Sino Biopharmaceutical Ltd shares (ISIN KYG8087W1029) trade under ticker 1177, giving investors direct exposure to this Chinese cancer-drug pipeline.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.